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Statins, the most prescribed class of drugs for the treatment of hypercholesterolemia, 
can cause muscle-related adverse effects. It has been shown that the glucocorti-
coid-induced leucine zipper (GILZ) plays a key role in the anti-myogenic action 
of dexamethasone. In the present study, we aimed to evaluate the role of GILZ in 
statin-induced myopathy. Statins induced GILZ expression in C2C12 cells, primary 
murine myoblasts/myotubes, primary human myoblasts, and in vivo in zebrafish 
embryos and human quadriceps femoris muscle. Gilz induction was mediated by 
FOXO3 activation and binding to the Gilz promoter, and could be reversed by the 
addition of geranylgeranyl, but not farnesyl, pyrophosphate. Atorvastatin decreased 
Akt phosphorylation and increased cleaved caspase-3 levels in myoblasts. This effect 
was reversed in myoblasts from GILZ knockout mice. Similarly, myofibers isolated 
from knockout animals were more resistant toward statin-induced cell death than 
their wild-type counterparts. Statins also impaired myoblast differentiation, and this 
effect was accompanied by GILZ induction. The in vivo relevance of our findings 
was supported by the observation that gilz overexpression in zebrafish embryos led 
to impaired embryonic muscle development. Taken together, our data point toward 
GILZ as an essential mediator of the molecular mechanisms leading to statin-induced 
muscle damage.
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1 |  INTRODUCTION
Statins are the first line of treatment in the management 
of hyperlipidemia and the prevention of cardiovascular 
disease (CVD).1,2 These drugs are inhibitors of the 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
enzyme, preventing the biosynthesis of cholesterol in the liver 
by blocking the mevalonate pathway and, as a consequence, 
enhancing clearance of circulating LDL-cholesterol.3,4 Since 
their introduction in 1987, statin prescription rates have risen, 
as shown by several studies in different populations,5-7 posi-
tioning them among the most prescribed drug classes world-
wide. Given the high prevalence of CVD and the favorable 
data on CVD prevention by statins,8,9 this tendency seems to 
be maintained.
Statins have a satisfactory safety profile, their most 
relevant adverse effect being skeletal muscle toxicity.1 
Statin-associated muscle symptoms (SAMS) have an in-
cidence of 5%-29% in clinical practice,1,10 can range from 
mild myalgia to, in rare cases, fatal rhabdomyolysis,11 
and are a frequent cause for nonadherence to treatment or 
its discontinuation.12 Although several studies have been 
conducted, and a number of risk factors that contribute 
to the onset of SAMS have been described, such as sex, 
pharmacokinetic differences, or genetic factors,13,14 the 
molecular mechanisms leading to myopathy are still not 
fully understood.
The glucocorticoid-induced leucine zipper (GILZ) was 
first described as a dexamethasone-induced, immunomod-
ulatory protein.15 Since then, it has been shown that GILZ 
basal expression is not restricted to immune cells but is 
extended to several tissues, including skeletal muscle.16 
GILZ plays multiple roles in both glucocorticoid and non-
glucocorticoid-mediated cellular processes17 beyond its 
immune-modulating function. For instance, studies demon-
strated a role for GILZ in inhibition of adipocyte differ-
entiation,18 in sodium homeostasis in the kidney,19,20 and 
in spermatogenesis.21 Of particular interest is the role de-
scribed for GILZ in the regulation of skeletal muscle dif-
ferentiation: GILZ is strongly induced by dexamethasone, 
mediating its antimyogenic effects via inhibition of the 
transcriptional activity of an early muscle regulatory factor 
(MRF), MyoD.22
In the present study, we aimed to test the hypothesis that 
GILZ plays a role in the onset of SAMS, focusing on both 
myotoxic and antimyogenic effects.
2 |  MATERIALS AND METHODS
2.1 | Reagents
Cell culture reagents, atorvastatin, simvastatin lactone, 
cerivastatin, and mevalonic acid lithium salt were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). The simvasta-
tin sodium salt, geranylgeranyl pyrophosphate (GGPP), and 
farnesyl pyrophosphate (FPP) were obtained from Cayman 
Chemicals (Ann Arbour, MI, USA). Statin stock solutions 
were prepared in DMSO.
2.2 | Cell line
C2C12 cells were maintained in high-glucose DMEM sup-
plemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 2 mM glutamine. For inducing differen-
tiation, confluent cell layers were cultured in high-glucose 
DMEM supplemented with 2% horse serum, penicillin/strep-
tomycin, and glutamine (differentiation medium, DM), with 
medium change every other day. All cells were cultured at 
37°C in a humidified atmosphere with 5% CO2. For experi-
ments, cells were seeded at a density of 2.5 × 104 cells/cm2 
(or 5 × 104 cells/cm2 for differentiation).
2.3 | Mice
C57BL/6J mice were housed in a 12/12-hour light/dark cycle 
with food and water ad libitum. GILZ knockout (KO) mice 
were generated as previously described.21 Animal care and 
maintenance were in compliance with regulations in Italy 
(DL 26/2014) and Europe (EU Directive 2010/63/EU).
2.4 | Flexor digitorum brevis (FDB) 
muscle fibers
FDB fibers were isolated from wild-type (WT) or GILZ KO 
mice following a protocol adapted from the literature.23,24 
The FDB muscles were dissected under a stereomicroscope 
and digested in a 0.2% collagenase A solution in DMEM for 
60 minutes. Then, the myofibers were carefully separated 
under a stereo dissecting microscope, dispersed in DMEM 
containing 10% horse serum by drawing through a series of 
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pipette tips with gradually decreasing diameter and purified 
by sedimentation steps. Pure fibers were plated in laminin-
coated cell culture dishes and cultured in DMEM supple-
mented with 20% serum replacement 2, 1% horse serum, 
penicillin/streptomycin, and glutamine.
2.5 | Primary human myoblasts
Primary human myoblasts (#CC-2580) were obtained from 
Lonza (Basel, Switzerland) and grown in Skeletal Muscle 
Growth Medium-2 (SkGM-2 basal medium, Lonza) with 
supplements (Lonza, #CC-3244 containing human epider-
mal growth factor, dexamethasone, L-glutamine, FCS, and 
gentamicin/amphotericin-B) according to the manufacturer’s 
instructions. For experiments, cells were seeded at a density 
of 1-1.5  ×  104 cells/well in SkGM-2 with all supplements 
except for dexamethasone.
2.6 | Primary murine myoblasts
Primary myoblasts were isolated from hind limbs of male 
3-day-old WT or GILZ KO mice. The hind limbs were 
dissected and shredded with scissors, washed in PBS, and 
digested with trypsin/EDTA for 60 minutes. After filter-
ing through a 70-µm cell strainer, the cell suspension was 
diluted in DMEM supplemented with 10% FBS and centri-
fuged for 20 minutes at 200×g and 4ºC. The resuspended 
cells were preplated for 1 hour to allow fibroblast adhesion. 
Nonadherent cells were collected, centrifuged for 10 min-
utes at 200×g and 4ºC, resuspended in F-10-based primary 
myoblast growth medium (Ham’s F-10 nutrient mixture sup-
plemented with 20% FBS, penicillin/streptomycin, and glu-
tamine), and plated onto collagen I-coated cell culture dishes 
(Sigma-Aldrich, St. Louis, MO, USA). Further enrichment 
of the myoblasts was achieved by dislodging and preplating 
the cells onto collagen-coated dishes every fourth day for 
1-2 weeks. Afterward, myoblasts were cultured in growth 
medium (40% DMEM, 40% Ham’s F-10 nutrient mixture, 
20% FBS), supplemented with penicillin/streptomycin and 
glutamine.
2.7 | Cytotoxicity measurement
For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reduction assay, cells were seeded in 96-well 
plates at a density of 104 cells/well, allowed to adhere over-
night, and treated with test compounds at the indicated concen-
trations. Cells incubated without any treatment were used as 
growth controls, cells incubated with solvent at the maximum 
concentration present in the assay (0.25%) served as negative 
controls, and wells with treatment but without cells were used 
as blank. At the end of treatment, cells were incubated for 3 
hours with MTT solution (0.5 mg/mL in medium) and lysed 
with DMSO. The absorbance was measured at 550 nm in a 
microplate reader (XFluor4 SunriseTM, TECAN, Männedorf, 
Switzerland), using a reference wavelength of 690 nm.
For the crystal violet assays, cells were seeded at a density 
of 104 cells/well into a 96-well plate. After overnight incuba-
tion, cells were treated with statins or vehicle control at the 
indicated concentrations. The cells were washed with PBS 
and incubated for 20 minutes with 50 μL/well of freshly pre-
pared 0.5% crystal violet solution in water. After washing, the 
plate was air-dried for 24 hours. Cells were lysed in methanol 
by incubation for 20 minutes at room temperature. The op-
tical density was measured at 570 nm. The background was 
determined by lysing cells with 50% DMSO before the stain-
ing procedure, and background-subtracted values were used 
to calculate the cell viability.
For evaluating the cell viability in FDBs, the number of 
living and nonliving myofibers was determined using the try-
pan blue exclusion method.
2.8 | RNA isolation, reverse 
transcription, and quantitative PCR (RT-
qPCR)
Total RNA from cultured cells was isolated using the High 
Pure RNA Isolation Kit (Roche, Basel, Switzerland). RNA 
samples with an A260/A280 ratio higher than 1.8 were used 
for further analysis. Reverse transcription was done using the 
High-Capacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific, Waltham, MA, USA) in the presence of 
RNase inhibitor (Thermo Fisher Scientific, Waltham, MA, 
USA). qPCR was performed on cDNA samples using the 
5×HotFirePol EvaGreen qPCR Mix (Solis BioDyne, Tartu, 
Estonia) and the primer sequences detailed in Table 1. A 
CFX96 touch Real-Time PCR detection system, and the 
CFX Manager 2.1 software (Bio-Rad, Hercules, CA, USA) 
were used for qPCR analysis. Data were analyzed as previ-
ously described.25 Housekeeping genes were chosen based 
on the literature, or after evaluating the expression stability of 
at least three candidate genes under the experimental condi-
tions, using the geNorm, NormFinder, and BestKeeper soft-
ware tools.26
2.9 | Western blot
Cells were harvested either with RIPA buffer (50 mM 
Tris-HCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium de-
oxycholate, 150 mM NaCl) supplemented with a protease/
phosphatase inhibitor mix (P8340, P0044, Sigma-Aldrich, 
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St. Louis, MO, USA) or with SB lysis buffer (50 mM 
Tris-HCl, 1% SDS, 10% glycerol, 5% β-mercaptoethanol, 
0.004% bromophenol blue, in water) supplemented with a 
protease inhibitor cocktail (cOmplete Mini, Roche, Basel, 
Switzerland). Western blots were performed as described 
previously, and signals were either detected by an HRP-
based method27 or with the LI-COR Odyssey imaging 
system (LI-COR Biosciences, Lincoln, NE, USA) .28,29 
Incubation with primary antibody dilutions was performed 
at 4°C overnight, and with secondary antibody dilutions at 
room temperature for 1-1.5 hours. The antibodies and dilu-
tions used are listed in Table 2.
2.10 | Jenner-Giemsa staining
To measure the myogenic differentiation of C2C12 myotubes 
Jenner-Giemsa staining was performed following a previ-
ously published protocol.30 In brief, cells were fixed in ice-
cold methanol for 5 minutes, air-dried, and stored at 4°C until 
analysis. For staining, wells were incubated with Jenner’s 
stain solution (diluted 1:3 in 1 mM sodium phosphate buffer 
pH 5.6) for 5 minutes at room temperature, washed with dis-
tilled water, and subsequently incubated with Giemsa solu-
tion (diluted 1:20 in the same buffer) for 10 minutes at room 
temperature. Wells were observed with a phase-contrast mi-
croscope equipped with a digital camera (ZEISS Axiovert 40 
CFL with Canon EOS 400D, Oberkochen, Germany). Each 
well was photographed in 3-4 randomly selected regions. 
Images were analyzed using the free image-processing soft-
ware Fiji (Fiji is just ImageJ) .31
2.11 | Immunofluorescence
Myosin heavy chain (MHC) immunofluorescence (IF) 
was performed on C2C12 myotubes and whole zebrafish 
embryos. Cells were cultured and differentiated on glass 
coverslips that were previously treated for 10 minutes in 
a 1:1 mixture of 70% ethanol and 0.1 N HCl.32 Cells were 
treated as indicated and prefixed by adding paraformalde-
hyde solution (4% in PBS) directly to the culture medium. 
After 2 minutes, the prefixation culture medium was re-
placed with a paraformaldehyde solution (4% in PBS), and 
cells were fixed for 15 minutes at room temperature. Cells 
were washed with PBS and permeabilized with a 0.2% 
Triton X-100 solution in PBS for 10 minutes at room tem-
perature, washed, blocked in a 5% BSA solution in PBS for 
1 hour at room temperature, and incubated with primary 
antibody (MF20, deposited by Donald A. Fischman in the 
Developmental Studies Hybridoma Bank, The University 
of Iowa, Department of Biology, Iowa City, IA, USA) di-
luted 1:50 in dilution buffer (1% BSA in PBS) at 4°C over-
night. After washing, cells were incubated with secondary 
antibody diluted 1:800 in dilution buffer for 1 hour at room 
temperature. Cells were washed and counterstained with 
DAPI for 15 minutes at room temperature, mounted with 
FluorSave (Merck, Darmstadt, Germany), and observed 
with an Axio Observer Z1 epifluorescence microscope, 
equipped with an AxioCam Mr3 and AxioVision software 
(Zeiss, Oberkochen, Germany). Photographs from randomly 
selected regions were analyzed using the Fiji software.
Zebrafish embryos were fixed in paraformaldehyde solu-
tion at 4°C overnight, and then stored in methanol at −20°C 
for at least 4 hours. Embryos were permeabilized in acetone 
for 30 minutes at −20°C, washed, blocked in a 1% BSA solu-
tion in PBST for 2 hours at room temperature, and incubated 
with primary antibody (mouse anti-myosin F59, DSHB, Iowa 
City, IA) diluted 1:100 in blocking buffer at 4°C overnight. 
After washing in PBST, the embryos were incubated with 
secondary antibody (goat anti-mouse IgG (H+L), Alexa 
Fluor 597, Thermo Fisher Scientific, Waltham, MA, USA) 
1:200 at room temperature for 4 hours, washed again, and 
observed on a Leica SP8 confocal microscope.
T A B L E  1  Primer sequences for qPCR analyses
Gene Accession number Forward primer sequence 5´-3´ Reverse primer sequence 5´-3´
Mouse
Csnk2a2 NM_009974.3 GTAAAGGACCCTGTGTCAAAGA GTCAGGATCTGGTAGAGTTGCT
Ppia NM_008907.1 GCGTCTCCTTCGAGCTGTTT CACCCTGGCACATGAATCCT
Hmgcr NM_008255.2 ATCCAGGAGCGAACCAAGAGAG CAGAAGCCCCAAGCACAAAC
Tsc22d3 NM_010286.4 GCTGCTTGAGAAGAACTCCCA GAACTTTTCCAGTTGCTCGGG
Human
RNA18S5 NR_003278.3 AGGTCTGTGATGCCCTTAGA GAATGGGGTTCAACGGGTTA
TSC22D3 NM_004089.3 CATGTGGTTTCCGTTAAGCTGG AGGATCTCCACCTCCTCTCTC
Zebrafish
actb2 NM_181601.4 AAATTGCCGCACTGGTT ACGATGGATGGGAAGACA
tsc22d3 NM_200569.2 AACAACCAGCTGGAGCGCGAA GCAGAGCCCGTGCTGCTGTATT
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2.12 | Zebrafish treatment
Zebrafish embryos from the AB wild-type strain were used. 
The developmental stage was determined by embryo mor-
phology in hours post fertilization (hpf).33 To examine gene 
expression after statin treatment, embryos at 19-22 hpf were 
sorted, placed at a density of 2-3 embryos/cm2 in 6-well 
plates, and incubated at 28°C in 0.3 × Danieau’s solution (17 
mM NaCl, 2 mM KCl, 1.5 mM HEPES, 1.8 mM Ca(NO3)2, 
0.12 mM MgSO4) containing 1 µM statin or solvent control. 
12 hours after treatment, 10-20 embryos were pooled, flash-
frozen in liquid nitrogen, and stored at −80°C for RNA iso-
lation and qPCR analysis. To analyze muscle development 
and movement of the embryos, gilz was overexpressed in ze-
brafish embryos by injecting 1200 pg RNA into 1-2 cell stage 
embryos.34 RNA was generated using the pCS2+ construct. 
Statin treatment was performed by injection of 1-ng statin 
(equal to 1/2 of the daily human dose related to body weight) 
into the embryos in the 1-2 cell stage.
The morpholino antisense oligonucleotides (MO) 
were purchased from Gene Tools (Philomath, OR, USA). 
To knockdown foxo3b, a splicing MO (foxo3b MO 
5′-TGGAGATGCACTGCGCTTACCTTCC-3′) targeting 
exon 2 and intron 2 was used as previously described.35 The 
Gene Tools random control oligo was used for comparison. 
MOs were dissolved in sterile water, and 1 nL containing 
16 ng MO were injected into 1-2 cell stage embryos. The 
knockdown was validated by detection of truncated PCR 
products in foxo3b morphants as described.35 The used prim-
ers were: foxo3b forward GTGAGTTACTGCTGGTGATGC 
(exon 1) and foxo3b reverse CACCACGAGCTCTTTCCAGT 
(exon 3).
2.13 | In situ hybridization
Whole-mount in situ hybridization was used to analyze 
MyoD expression changes in zebrafish embryos. Embryos 
at 16 hpf were collected and fixed in 4% PFA solution at 
4°C overnight. In situ hybridization was performed as pre-
viously described.32 In brief, dechorionated embryos were 
treated with 5 µg/µL proteinase K in PBST for 5 minutes, 
washed and incubated for 1 hour in hybridization buffer (50% 
formamide, 5× SSC, 0.1% Tween 20, 1 mg/mL yeast torula 
RNA, 50 µg/mL heparin) at 65°C. Subsequently, an antisense 
digoxigenin-labeled RNA probe was added, and the samples 
were incubated overnight. On the next day, embryos were 
washed, blocked for 1 hour (5% goat serum in PBST) and 
incubated with anti-DIG antibody (#11093274910, 1:5000, 
Roche, Basel, Switzerland) at 4°C overnight. Embryos were 
washed in AP buffer (100 mM Tris-HCl, 50 mM MgCl2, 
100 mM NaCl, 0.1% Tween20), and incubated with stain-
ing buffer (0.5% nitroblue tetrazolium, 0.375% 5-bromo-4-
chloro-3-indolyl phosphate in AP buffer) in the dark for 30 
T A B L E  2  Antibodies for Western blot analyses
Antibody Dilution
Rat anti GILZ [CFMKG15] mAb (Thermo Fisher Scientific, Waltham, MA, USA) For detection with HRP-labeled secondary antibodies:
1:1000 in 5% milk powder—TBST
For detection with IR-labeled secondary antibodies:
1:1000 in Rockland blocking buffer
(Rockland, Limerick, PA, USA)
Mouse anti GADPH [OTI2D9] (OriGene, Rockville, MA, USA) 1:2000 in 5% milk powder—TBST
Mouse anti Akt (pan) [40D4] mAb (New England Biolabs, Ipswich, MA, USA) 1:2000 in 5% milk powder—TBST
Rabbit anti phospho-Akt (Ser473) [D9E] XP® mAb (New England Biolabs, 
Ipswich, MA, USA)
1:2000 in 5% milk powder—TBST
Polyclonal rabbit anti phospho-FOXO3a (Ser253) (New England Biolabs, 
Ipswich, MA, USA)
1:2000 in 5% milk powder—TBST
Mouse anti FOXO3a [D12] mAb (Santa Cruz Biotechnology, Dallas, TX, USA) 1:1000 in gelatine buffer (0.75% gelatine A , 0.1% Tween-
20, 20 mM Tris, 137 mM NaCl, pH 7.5)
Mouse anti myogenin [5FD] mAb (Santa Cruz Biotechnology, Dallas, TX, USA) 1:200 in 5% milk powder—TBST
Polyclonal rabbit anti cleaved Caspase-3 (Cell Signaling Technology, Beverly, 
MA, USA)
1:1000 in 5% milk powder—TBST
Goat anti-rat IgG (H+L), HRP (Thermo Fisher Scientific, Waltham, MA, USA) 1:5000 in 5% milk powder—TBST
Goat anti-mouse IgG (H+L), HRP (Thermo Fisher Scientific, Waltham, MA, 
USA)
1:5000 in 5% milk powder—TBST
Goat anti-rabbit IgG, HRP (Thermo Fisher Scientific, Waltham, MA, USA) 1:10 000 in 5% milk powder—TBST
Mouse anti-α-Tubulin [DM1A] (Sigma-Aldrich, St. Louis, MO, USA) 1:1000 in Rockland blocking buffer
IRDye 800CW Goat anti-Rat IgG (LI-COR Biosciences, Lincoln, NE, USA) 1:10 000 in Rockland blocking buffer
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minutes. Once the pattern appeared, embryos were washed, 
and 4% PFA was added for at least 20 minutes before em-
bryos were analyzed under the microscope. Scoring was 
performed according to the following criteria: regular phe-
notype—parallel somites of same length, V-shaped, homog-
enous MyoD expression; mild phenotype—irregular somite 
formation, different lengths, line shaped, somites show less 
homogenous MyoD expression; severe phenotype: no clear 
somite formation, different lengths, line shaped, reduced and 
diffuse MyoD expression.
2.14 | Chromatin immunoprecipitation 
(ChIP)
The ChIP assay was performed using the EZ-ChIP Kit 
(Merck, Darmstadt, Germany) according to the manufactur-
er’s instructions. Precleared lysates from 1 × 106 myoblasts 
in a volume of 100 µL were incubated overnight at 4°C with 
10 µg monoclonal anti-FOXO3 antibody (D12, Santa Cruz 
Biotechnology, Dallas, TX, USA) or 10 µg normal mouse 
IgG (Merck, Darmstadt, Germany). Immunocomplexes were 
purified, and qPCR analysis was performed using the SYBR 
Select Master Mix (Thermo Fisher Scientific, Waltham, MA, 
USA) and the Applied Biosystems 7300 qPCR system (Foster 
City, CA, USA). Primer sequences are given in Table 3.
2.15 | Luciferase gene reporter assay
Reporter gene assays were performed as previously de-
scribed.25 The proximal Gilz promoter (a fragment located 
between −1938 bp upstream and +206 bp downstream of the 
transcription start site) was cloned into the pGL3 luciferase 
reporter vector (Promega, Madison, WI, USA) using KpnI 
and SmaI according to the manufacturer’s instructions. The 
FOXO3 reporter vector (FHRE-Luc) was a gift from Michael 
Greenberg (Addgene plasmid #1789).36 The phRG-TK vector 
(Promega, Madison, WI, USA) provided constitutive expres-
sion of Renilla luciferase and served as an internal control 
value, to which expression of the firefly luciferase reporter 
gene was normalized. C2C12 cells were seeded at a density 
of 104 cells/well into 96-well plates, co-transfected in a 1:1 
ratio with the luciferase vector using the Lipofectamine 3000 
reagent (Thermo Fisher Scientific, Waltham, MA, USA) for 
4 hours, treated as indicated, and harvested by the addition 
of 1× passive lysis buffer (Promega, Madison, WI, USA). 
Luciferase activity was determined by the addition of fire-
fly luciferase substrate (470 µM D-luciferin, 530 µM ATP, 
270 µM coenzyme A, 33 µM DTT, 20 µM Tricine, 2.67 µM 
MgSO4, 1.07 µM MgCO3, and 0.1 µM EDTA, pH 7.8) or 
renilla substrate solution (0.1 M NaCl, 25 mM Tris HCl pH 
7.5, 1 mM CaCl2, and 0.9 µM coelenterazine) followed by 
luminescence measurement using the Glomax Discover mul-
tiplate reader (Promega, Madison, WI, USA).
2.16 | Lentivirus preparation
Plasmids encoding lentiviral products were obtained from 
Addgene (Watertown, MA, USA). The packaging plasmid 
psPAX2 and the envelope plasmid pMD2.G were a gift from 
Didier Trono (Addgene plasmids #12260 and #12259). The 
pLKO.1-TRC cloning vector was a gift from David Root 
(Addgene plasmid #10878).37 pLKO.1-scrambled shRNA 
was a gift from David Sabatini (Addgene plasmid #1864).38
Two different sequences of short hairpin (sh) RNA target-
ing murine GILZ were used: shGILZ1 (5′-GGAGTACTGA 
CTGGTCTCTTA-3′), and shGILZ2 (5′-ACAGCTTCACCT 
GACAATG-3′). shGILZ sequences were cloned into the 
pLKO.1-TRC cloning vector. In brief, the cloning vector was 
double digested with AgeI-HF and EcoRI-HF and purified 
from an agarose gel. The annealed oligos were then ligated 
into the vector using T4 DNA ligase overnight at room tem-
perature. The ligation mix was transformed into GT116 E. 
coli (Invivogen, Toulouse, France), and ampicillin-resistant 
clones were screened for inserts by sequencing using the 
pLKO.1 sequencing primer.
Lentiviral particles were produced following Addgene’s 
protocol. Briefly, 5 × 105 HEK-293T cells were plated into 
6-cm cell culture dishes in medium without antibiotics and 
transfected at 50%-80% confluency with the transfer, pack-
aging and envelope plasmids (1000:750:250) using the 
FuGENE 6 Transfection Reagent (Promega, Madison, WI, 
USA). Twelve to 15 hours after transfection, the medium was 
replaced with DMEM. The lentivirus-containing media were 
T A B L E  3  Primer sequences for ChIP experiments




FHRE4 (IRE, insulin-responsive element) AGAGCTTTCTTGGTCTGAGAGAAT AATTTTGAGGTGAGTAGCAGTAGT
non-FHRE GTATTCGGCCTTCTCCTTGC CTGCTGCGTGGTGAAAAACA
4690 |   HOPPSTÄDTER ET al.
then harvested at 24 and 48 hours, pooled, centrifuged at 
200×g for 5 minutes, aliquoted, and stored at −20°C.
To determine the lentiviral titer, viral genomic RNA was 
purified from 200 µL of freshly harvested lentivirus stock using 
the High Pure Viral RNA Kit (Roche, Basel, Switzerland). 
After digestion of residual DNA, 10-fold serial dilutions of 
the purified viral RNA were reverse transcribed and ampli-
fied via qPCR, using primers for the 5′LTR region (forward 
5′-AGCTTGCCTTGAGTGCTTCA-3′, reverse 5′-TGA 
CTAAAAGGGTCTGAGGGA-3′), and the 5′ end of the gag 
gene (forward 5′-GGAGCTAGAACGATTCGCAGTTA-3′, 
reverse 5′-TGTAGCTGTCCCAGTATTTGTC-3′). The copy 
number (viral particles, VP) contained in the supernatant 
was calculated from comparison against a plasmid standard 
curve, and the titer calculated as viral particles per ml of su-
pernatant (VP/mL). Biological titration of the vectors was 
performed via limiting dilution, and for each lentivirus, the 
ratio from biological to nonbiological titer was established 
and used for estimation of the functional titer (TU/mL) for 
all further preparations that were only titrated via the gRNA 
method. This titer was then used to determine the volume of 
viral supernatant needed for infecting cells at a given multi-
plicity of infection (MOI).
2.17 | Generation of C2C12shGILZ stable 
cell lines
Stable, polyclonal C2C12 cell lines were generated by re-
verse transducing 7.5 × 104 cells in 6-well plates with scram-
bled shRNA, shGILZ1, or shGILZ2 lentiviral particles at 
an MOI of 10 in the presence of polybrene, following the 
protocol for the generation of stable cell lines available from 
Addgene (Watertown, MA, USA). Twenty-four hours after 
transduction, the medium was changed, and 48 hours after 
infection puromycin (2 µg/mL) was added to select for trans-
duced cells. The puromycin-resistant cells were expanded 
for 2-3 weeks, after which they were harvested for analysis 
of gene and protein expression. Further culture and experi-
ments were done in 1 µg/mL puromycin-containing medium. 
A nontransduced control was run in parallel to confirm that 
no viable cells were present after selection.
2.18 | Muscle biopsies and sample 
preparation
Two percutaneous muscle biopsies from the musculus vastus 
lateralis were obtained from a hypercholesteremic volunteer 
to determine GILZ baseline expression levels. After the onset 
of simvastatin treatment (40 mg/d), biopsies were obtained 
after 1-3 months. Semi-automatic needle biopsies were alter-
nately performed on the right and left legs of the participant 
using the Bard Magnum device with a 12-G disposable needle 
(C.R. Bard Gm bH, Karlsruhe, Germany). Local anesthesia 
of the skin and subcutaneous tissue was performed accord-
ing to standard procedures using Lidocaine as an anesthetic. 
Muscle samples were immediately frozen in liquid nitrogen 
and stored at −80°C. Skeletal muscle biopsy samples were 
mechanically homogenized using a Precellys homogenizer 
(Bertin Corp., Rockville, MD, USA). RNA was isolated using 
the miRNeasy Micro Kit according to the manufacturer’s in-
structions (Qiagen, Venlo, Netherlands). Reverse transcrip-
tion and quantitative PCR was performed as described above.
2.19 | Statistics
Results are expressed as means of at least three independent 
experiments performed in replicates ± SEM (standard error 
of the mean). Statistically significant differences between 
means were determined using the GraphPad Prism 6.0 or 
Origin 2018b software. An unpaired t test was performed for 
the comparison of two groups, and the comparison of three or 
more groups was carried out by one or two-way analysis of 
variance (ANOVA) followed by Bonferroni’s post hoc analy-
sis for individual differences. For MTT results F values and 
degrees of freedom were indicated. A comparison between 
medians was performed with Kruskal-Wallis test followed by 
Dunn’s post hoc analysis. For categorical data, the chi-squared 
test was used. Results were considered significant at P < .05.
3 |  RESULTS
3.1 | GILZ expression in human muscle 
biopsies
To investigate the potential effect of statin treatment on GILZ 
expression, we analyzed different publicly available gene ex-
pression profiling data sets. Gene Expression Omnibus (GEO) 
data sets GDS2987, GSE32547, and GSE4883 suggested 
that statins were able to induce GILZ in human endothelial 
cells, human pulmonary artery smooth muscle cells, human 
umbilical vein endothelial cells, and human peripheral blood 
monocytes (Supplemental Figure 1). Interestingly, statins also 
induced GILZ in a clinical setting: The analysis of a transcrip-
tional profile of human quadriceps femoris muscle following 
statin treatment suggested a moderate increase in GILZ ex-
pression in biopsies from 12 patients receiving atorvastatin 
and simvastatin for 8 weeks, compared with those receiving 
placebo (ArrayExpress dataset E-TABM-116, Figure 1).39 
These results were in accordance with increased GILZ mRNA 
levels observed in muscle biopsies from a hypercholester-
olemic volunteer after simvastatin treatment (Supplemental 
Figure 2).
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3.2 | Toxic concentrations of statin induce 
GILZ expression in muscle cells
To evaluate whether statins were able to induce GILZ in skel-
etal muscle cells, we treated C2C12 myoblasts and myotubes 
with 50 µM atorvastatin, simvastatin, or cerivastatin. These 
relatively high statin concentrations are in accordance with 
the literature34,40-43 and were also chosen based on our ob-
servation that C2C12 myoblasts in cell culture express a 50-
fold higher Hmgcr baseline level compared to muscle in vivo 
(Supplemental Figure 3). Statins were toxic after 24 hours—but 
not after 6 hours—at this concentration, as determined by MTT 
and crystal violet assay (Supplemental Figure 4). We detected 
an increase in Gilz mRNA expression in C2C12 myoblasts and 
primary human myoblasts after 6 hours of treatment with all 
statins, which was reversed by the addition of mevalonate (100 
µM) to the medium, indicating that the mechanism of GILZ in-
duction relates to the inhibition of HMG-CoA reductase (Figure 
2A). In C2C12 myotubes, the increase in Gilz expression was 
less pronounced (Figure 2A). Western blot analysis showed an 
elevated expression of GILZ protein in C2C12 myoblasts as 
well as in primary murine and human myoblasts treated with 
toxic concentrations of statins (Figure 2B-D).
3.3 | GILZ induction can be reversed by 
geranylgeranyl pyrophosphate
The inhibition of HMG-CoA by statins does not only im-
pair cholesterol biosynthesis, but also other biosynthetic 
pathways. Of main importance is the inhibition of protein 
prenylation resulting from the decreased synthesis of the 
isoprenoid derivatives GGPP and FPP. Thus, we evaluated 
whether GILZ induction could be reversed by the addition of 
any, or both, of these mediators to the medium. Co-treatment 
of C2C12 myoblasts with 10 µM GGPP in addition to simv-
astatin completely reversed Gilz induction, while FPP had no 
effect (Figure 2E). GGPP treatment alone did not affect Gilz 
expression (data not shown).
3.4 | Statin-induced impairment of 
myogenesis is accompanied by GILZ induction
Myogenesis is a multistep, tightly regulated process that 
leads to the formation of skeletal muscle, both during embry-
onic development as well as in adult life, to maintain mus-
cle homeostasis and repair after injury.44 Statins are not only 
toxic toward skeletal muscle fibers but might also impair the 
muscle regeneration process.45-47 To examine these effects, 
we induced the differentiation of C2C12 myoblasts in the 
absence or presence of statins and evaluated myotube for-
mation by Jenner-Giemsa staining and myosin heavy chain 
immunofluorescence. We observed that treatment of C2C12 
cells with subtoxic concentrations of statins during differen-
tiation resulted in less myotube formation and a significantly 
reduced fusion index after 6 days, where fully differentiated 
myotubes were visible in the control (Figure 3A-C). We ana-
lyzed GILZ expression levels in differentiating C2C12 and 
primary murine myotubes treated with statins and found that 
the impairment in myogenesis was accompanied by GILZ 
induction on both mRNA and protein level (Figure 3D,E). 
Since GILZ has been shown to mediate the antimyogenic ef-
fects of dexamethasone,22 we hypothesized that it might also 
be involved in the effects observed after statin treatment.
3.5 | GILZ knockout abolishes the cytotoxic 
effects of statins
To assess whether loss of GILZ could rescue statin-induced 
cytotoxicity, we isolated primary myoblasts from wildtype 
F I G U R E  1  Analysis of the publicly available ArrayExpress 
dataset E-TABM-116: transcription profiling of human quadriceps 
femoris muscle following simvastatin (80 mg/d) and atorvastatin 
(40 mg/d) treatment. A, GILZ signal intensities (NCBI RefSeq 
NM_004089.3; scan REFs GI_37622900-A, GI_37622900-I) are 
shown. Connected data points represent patients before and after 
intervention for 8 weeks. B, GILZ expression after intervention is 
presented as x-fold of individual baseline levels. Boxplots show the 
25-75th percentiles, mean (square), median (line) and SD (whiskers). 
Placebo group: n = 6, statin group: n = 12. *P < .05  
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(WT) and GILZ knockout (KO) mice, treated them with in-
creasing doses of statins, and measured cell viability after 
24 hours. Comparison of the dose-response curves obtained 
showed significant differences between genotypes: GILZ 
KO myoblasts were significantly less sensitive toward atorv-
astatin, simvastatin, and cerivastatin treatment than their WT 
counterparts (Figure 4A).
Due to the importance of the PI3K/Akt signaling path-
way in statin-induced myotoxicity,40,42 we hypothesized that 
the resistance to cell death from GILZ KO myoblasts might 
be related to modulation of the Akt phosphorylation status. 
Indeed, atorvastatin treatment induced dephosphorylation 
of Akt and activated the apoptotic pathway, as observed by 
cleaved caspase-3 detection, in WT myoblasts. On the other 
hand, Akt phosphorylation levels were restored to that of the 
control in statin-treated GILZ KO cells, and the active form 
of caspase-3 was undetectable (Figure 4B,C).
As an ex vivo model for the evaluation of statin myotoxicity, 
we used flexor digitorum brevis myofibers isolated from WT 
and KO animals. These short fibers can be isolated, dissociated, 
and cultured, representing a more mature system for evaluation 
of statin effects than cell culture systems, since myoblasts in 
F I G U R E  2  Effect of statin treatment at toxic concentrations on GILZ expression in muscle cells. A, C2C12 myoblasts, C2C12 72-h 
myotubes, or primary human skeletal muscle myoblasts were treated with 50 µM statin (Ator, atorvastatin; Sim, simvastatin; Ceri, cerivastatin) 
in the absence or presence of mevalonate (MVA, 100 µM) for 6 hours, and mRNA levels were determined by qPCR. Gilz expression in C2C12 
samples was normalized to the housekeeping gene Csnk2a2, and GILZ expression in human samples was normalized to RN18S5. Data are presented 
as fold change of control. B-D, GILZ protein expression was determined in vehicle- or atorvastatin-treated C2C12 myoblasts (B), primary murine 
myoblasts (C), and primary human skeletal muscle myoblasts (D) by western blot. Representative blots and densitometric analyses are shown. For 
densitometric analysis, GILZ signal intensities were normalized to the housekeeping protein GAPDH (B, C) or tubulin (D). E, C2C12 myoblasts 
were treated with 50 µM simvastatin in the absence or presence of GGPP and FPP (10 µM) for 6 hours, and Gilz mRNA levels were measured. 
mRNA expression was normalized to the housekeeping gene (Csnk2a2) and is presented as fold change of control. Data show the mean of 2 (A, 
C2C12 data) or 3 (A, human myoblast data and B-E) independent experiments performed in replicates ± SEM. **P < .01, ***P < .001 relative to 
the corresponding control, ++P < .01, +++P < .001 relative to other treatments as indicated
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vitro can differentiate to myotubes but are unable to form fully 
differentiated myocytes and, therefore, do not exactly resem-
ble the features of mature muscle.48,49 Treatment of FDB fibers 
from WT mice with atorvastatin, simvastatin, and cerivastatin 
started to induce vacuolation at 72 hours. After 5 days, the fibers 
were swollen, ruptured, and blebs appeared (Figure 5A and data 
not shown). Viability analysis using the trypan blue exclusion 
method after 5 days indicated that statins induced fiber death in 
a dose-dependent manner. Loss of GILZ prevented the morpho-
logical changes indicative of myotoxicity and made the fibers 
resistant toward statins: in KO fibers, there were no significant 
differences in viability between the control and treatments at 
any of the concentrations evaluated (Figure 5A,B).
3.6 | GILZ contributes to statin-induced 
inhibition of myogenesis
To investigate the contribution of GILZ to statin-induced inhi-
bition of myogenesis, we differentiated WT and GILZ KO my-
oblasts in the presence of statins and evaluated the expression 
of the MRF myogenin, which is required in cells committed 
F I G U R E  3  Effect of statins on GILZ expression during C2C12 differentiation. A-B, C2C12 were induced to differentiate for 6 days in the 
absence or presence of nontoxic concentrations of atorvastatin (5 µM), simvastatin (1 µM), and cerivastatin (0.1 µM), and subjected to MHC IF. 
Co: vehicle-treated cells. A, Representative images are shown. Blue: DAPI, green: MHC, scale bar: 50 µm. B, The degree of differentiation was 
quantified by measuring the fusion index in IF images. C, Myotube density in Jenner-Giemsa stained cells. D, Gilz expression was measured in 
nondifferentiated cells or cells differentiated for the indicated time points and normalized against the housekeeping gene (Csnk2a2). Data are 
presented as fold change of the corresponding vehicle-treated control (Co). E, GILZ protein levels measured in 72 h-C2C12 myotubes and primary 
murine myotubes treated with atorvastatin (5 µM) during the course of myogenesis. Representative blots are shown. Data represent the means  
of three independent experiments performed in replicates ± SEM. *P < .05, **P < .01, ***P < .001 relative to the control  
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to the myogenic program for driving their fusion and terminal 
differentiation.44 We observed a decrease in myogenin protein 
levels in WT primary murine myoblasts induced to differenti-
ate for 72 hours in the presence of atorvastatin. By contrast, the 
expression of myogenin in atorvastatin-treated GILZ KO cells 
was restored to that of the control (Figure 6A).
To further analyze the role of GILZ in these effects, 
we generated C2C12 cell lines stably expressing scram-
bled or Gilz shRNA constructs by lentiviral transduction. 
The C2C12shGilz1 and C2C12shGilz2 cell lines showed a gene 
knockdown, whereas in the scrambled control cell line, 
C2C12scr, Gilz expression was unaffected (Supplemental 
Figure 5A). Furthermore, statin-induced GILZ overex-
pression was inhibited in Gilz shRNA-expressing cells 
(Supplemental Figure 5B,C). We hypothesized that, as a re-
sult of restored myogenin expression, Gilz silencing should 
reinstate the ability of myoblasts to differentiate in the pres-
ence of statins. Noticeably, C2C12shGilz1 and C2C12shGilz2 
cells displayed terminally differentiated myotubes already 
after 4 days in DM, whereas C2C12scr cells were not fully 
differentiated yet (Figure 6B, left panels). GILZ knock-
down, however, could only partially reverse the impairment 
in differentiation caused by statins: although Jenner-Giemsa 
staining showed myotube formation in the C2C12shGilz lines 
(Supplemental Figure 6), these myosin-expressing cells were 
not differentiated to the same extent as the respective con-
trols. Nevertheless, fusion index analysis showed improve-
ment in myotube formation from C2C12shGilz cells compared 
to the C2C12scr line (Figure 6C).
3.7 | FOXO3 mediates GILZ induction by 
statins in muscle
In the search for potential upstream regulators of GILZ ex-
pression after statin treatment in muscle, we focused on the 
Forkhead Box O3 (FOXO3) protein. FOXO3 is a direct phos-
phorylation target of Akt, and our observations in skeletal 
muscle tissue from FOXO3 KO mice, where Gilz expression 
levels were significantly lower than in WT animals, hinted to-
ward FOXO3 as a transcriptional regulator of GILZ in this tis-
sue (Figure 7A). Reporter gene assay showed that statins were 
able to induce FOXO3 transcriptional activity (Supplemental 
Figure 7) and, in fact, led to increased Gilz promoter-driven 
luciferase activity in C2C12 compared to the baseline. This 
indicates that statins elevate GILZ levels by activating its 
transcription (Figure 7B). Like in primary myoblasts, we 
observed that treatment of C2C12 myoblasts with statins led 
F I G U R E  4  Effect of GILZ knockout on statin-induced myotoxicity. A, WT and GILZ KO primary murine myoblasts were treated with 
atorvastatin, simvastatin, or cerivastatin in increasing concentrations for 24 hours. Cell viability was measured via MTT assay and differences 
between curves were analyzed by two-way ANOVA [cell type main effect F(1,124) = 10.06, P = .002; F(1,124) = 26.24, P < .0001; 
and F(1,116) = 24.18, P < .0001, respectively, for each statin]. B, Myoblasts were treated with atorvastatin (50 µM) for 6 hours, and Akt 
phosphorylation and caspase-3 activation were measured by western blot. One representative blot is shown. C, The ratio of phosphorylated to 
total Akt was measured by densitometric analysis and normalized to the corresponding control. Data show the mean of at least three independent 
experiments performed in replicates ± SEM. *P < .05, **P < .01, ***P < .001 relative to the control
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to a decrease in Akt phosphorylation and, in line with this, 
to reduced levels of phosphorylated FOXO3 protein, that 
is, FOXO3 activation in parallel to GILZ induction (Figure 
7C-E). Hence, we performed chromatin immunoprecipita-
tion to evaluate whether FOXO3 activated Gilz expression 
in myoblasts by binding to the forkhead-responsive elements 
(FHRE) in its promoter following statin treatment. Indeed, we 
found an enrichment of sequences corresponding to three of 
the four FHREs presents in the Gilz promoter in immuno-
precipitates from atorvastatin-treated myoblasts, indicating 
that GILZ induction in muscle follows dephosphorylation, 
nuclear translocation, and activation of FOXO3 (Figure 7F).
3.8 | Statins induce Gilz in zebrafish 
embryos, and deregulation of Gilz expression 
impairs somitogenesis
The zebrafish is a powerful and versatile in vivo model for 
the study of developmental and physiological processes, that 
has been used for the elucidation of statin effects on mus-
cle development50 and homeostasis.41,51,52 Given that the ze-
brafish expresses a GILZ orthologue,53 we chose this model 
to study the effects of statins on GILZ expression in vivo 
adhering to 3R rules to reduce animal experiments.
In line with our in vitro findings, treatment of zebrafish 
embryos at 20 hpf with statins at concentrations that have 
been described to cause major muscle damage34 led to an up-
regulation of gilz mRNA (Figure 8A). Moreover, statin treat-
ment of embryos in the 2-4 cell stage for 24 hours resulted 
in disrupted muscle development in the tail of the embryos 
and a reduction of the frequency and dimension of muscle 
contractions, indicating an impaired muscle function (Figure 
8B, Supplemental video). To characterize the effects of in-
creased gilz expression in zebrafish muscle development, 
we performed myosin heavy chain IF and MyoD staining in 
gilz overexpressing and statin-treated embryos. Compared to 
control animals, we found an irregular MyoD expression and 
diffuse MHC staining with loss of septa in statin-treated em-
bryos. Overexpression of gilz mimicked statin effects, sug-
gesting that gilz mediated statin-induced muscle damage in 
this model (Figure 8C,D).
To investigate whether FOXO3b, the orthologue of mam-
malian FOXO3, was involved in gilz upregulation by statins, 
we knocked down foxo3b by morpholino injection.35 gilz lev-
els were reduced in foxo3b depleted embryos (Supplemental 
Figure 8). It was not possible to assess statin-induced muscle 
damage after morpholino-mediated knockdown of foxo3b 
because the embryos showed severe defects in axis forma-
tion, as previously reported by Xie et al35 (Supplemental 
Figure 8B).
4 |  DISCUSSION
More than 30 years after their introduction to the market, 
statins remain the cornerstone of the pharmacological man-
agement of hyperlipidemia and CVD prevention. In light 
of their importance and extended use, the understanding of 
the mechanisms underlying the onset of SAMS is of highest 
relevance.10 In the present study, we report a role for GILZ 
as a pivotal mediator of the myotoxic and antimyogenic ef-
fects of statins. We first demonstrate that treatment of murine 
myoblasts with different statins, at concentrations typical for 
in vitro studies on SAMS,41,43,54 induces GILZ expression. 
Since SAMS are a class effect and several of the mechanisms 
underlying muscle toxicity are directly related to the inhibi-
tion of HMG-CoA,47,55 we evaluated whether GILZ expres-
sion depended on this pathway as well. Indeed, we found 
GILZ induction to depend on mevalonate, and more specifi-
cally on geranylgeranylation.34
Several molecular mechanisms of statin-induced myotox-
icity have been proposed, describing their deleterious effects 
F I G U R E  5  Effect of GILZ knockout on statin-induced 
FDB myofiber toxicity. WT and GILZ KO FDB myofibers were 
treated with cerivastatin (1 µM) for up to 120 hours and imaged 
for morphological analysis. A, Representative pictures are shown. 
Scale bar, 20 µm. B, Cell viability was measured after 120 hours of 
treatment, using the trypan blue exclusion method. Data show the 
mean of four independent experiments performed in replicates ± SEM. 
*P < .05, ***P < .001 relative to the corresponding control
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on mitochondrial function, calcium homeostasis, and cell 
survival in the myocyte.14 In our hands, statins caused Akt 
dephosphorylation and activation of the apoptotic cascade in 
undifferentiated myoblasts. This effect is in accordance with 
previous findings in cultured myotubes.42,56 Our observations 
suggest a crucial role for GILZ in mediating this action. First 
described in thymocytes as an antiapoptotic protein,15 GILZ 
can exert anti- or pro-apoptotic effects depending on the cell 
type: GILZ has been shown to promote apoptosis by Mcl-1 
downregulation in neutrophils57 and by inhibition of the Akt/
mTOR signaling pathway in myeloma cells.58
There are discrepancies, however, regarding the mech-
anism by which statins induce cell death in cultured myo-
blasts/myotubes vs. mature fibers. For instance, statins trigger 
apoptosis in cultured cells, whereas mature skeletal muscles 
show necrotic features.49 Hence, instead of using terminally 
F I G U R E  6  Effect of GILZ absence on statin-induced antimyogenic effects. A, Primary murine myoblasts from GILZ WT and KO animals 
were differentiated for 72 hours in the absence or presence of atorvastatin (5 µM). Myogenin protein levels were measured by western blot. One 
representative blot and the densitometric analysis are shown. B-C, Scrambled (C2C12scr) and C2C12shGILZ cell lines were induced to differentiate 
for 4 days in the absence or presence of atorvastatin (5 µM), simvastatin (1 µM), and cerivastatin (0.1 µM). Co: vehicle-treated cells. B, MHC IF. 
Blue: DAPI, green: MHC, scale bar: 50 µm. Representative images are shown. C, The degrees of differentiation was quantified by measuring the 
fusion index. For statin-treated cells the fusion index is expressed as percentage of the corresponding vehicle-treated control. Data show the mean 
of at least three independent experiments performed in replicates ± SEM. *P < .05, **P < .01, ***P < .001 relative to the equally treated scr cells 
(C) or as indicated (A) 
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differentiated cultured myotubes, we chose isolated FDB 
myofibers as an ex vivo model to evaluate the effects of the 
absence of GILZ in statin toxicity toward mature muscle. 
We noticed that treatment of murine FDB fibers with ator-
vastatin, simvastatin, and cerivastatin caused cell death with 
similar features as those previously described for fluvasta-
tin-treated rat FDB fibers.59 Furthermore, in accordance with 
our observations in proliferating myoblasts, GILZ was of cru-
cial importance in mediating statin-induced fiber breakdown.
FOXO3 is a transcription factor involved in different aspects 
of muscle homeostasis, like regulation of mitochondrial metab-
olism, activation of protein breakdown via the ubiquitin-pro-
teasome and autophagy pathways, and inhibition of muscle 
precursor cell proliferation.60 In statin-induced myopathy, re-
ports have shown that FOXO3 activation results in expression of 
the muscle atrophy-related protein MAFbx/atrogin-1 and other 
genes implicated in muscle proteolysis in vitro and in vivo.40,41 
Moreover, FOXO3 has been reported as a transcriptional regula-
tor of GILZ in T cells, where it drives IL-2 withdrawal-induced 
GILZ expression.61 We found statin-induced GILZ expression 
in muscle to be FOXO3-dependent and, as mentioned above, 
GGPP dependent. These results are in accordance with previ-
ous studies that linked SAMS to reduced geranylgeranylation, 
but not farnesylation of different small GTPases like Rac1, 
Rap1, and Rab1.34,45,56,62 Our findings suggest that the inhibi-
tion of protein geranylgeranylation by statins downregulates the 
F I G U R E  7  Involvement of FOXO3 in statin-induced GILZ expression. A, Gilz expression on skeletal muscle from WT and FOXO3 KO 
mice (n = 5). mRNA expression data normalized against the housekeeping gene (Csnk2a2) and is presented as fold change of WT in boxplots 
showing the 25-75th percentiles, mean (square), median (line), and SD (whiskers). B, Reporter gene assay in C2C12 myoblasts transfected with 
a Gilz promoter reporter plasmid and treated with vehicle (Co) or statins (50 µM) for 6 hours. Luciferase activity was normalized to the vehicle-
treated control. C-E, Western blot analysis of statin-treated C2C12 cells (50 µM, 6 hours; Co: vehicle control). C, One representative blot is shown. 
D-E, Densitometric analysis. Values for vehicle-treated controls were set as 1. F, ChIP analysis was used to detect the binding of FOXO3 to the 
Gilz promoter region. Data are presented as fold enrichment over IgG. Data show the mean of at least three independent experiments performed in 
replicates ± SEM. *P < .05, **P < .01, ***P < .001 relative to the vehicle-treated control
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Akt signaling pathway, leading to FOXO3-driven GILZ induc-
tion, which in turn further decreases Akt phosphorylation and 
promotes apoptosis of muscle cells.
The fact that GILZ is expressed in skeletal muscle, as ob-
served by us and reported in earlier studies,16 might denote 
a role in muscle tissue homeostasis. Indeed, an earlier study 
showed that GILZ and its longer isoform, L-GILZ, modulate 
myogenesis in the absence of pharmacological intervention, 
and mediate glucocorticoid-induced inhibition of myogenesis 
by decreasing MyoD-mediated myogenin transcription, thus 
impairing myoblast fusion.22 For this reason, we investigated 
the role of GILZ in the antimyogenic effects of statins and 
found that the degree of GILZ induction during myogenesis 
was correlated to the antimyogenic effect of the statin used. 
A previous study reported no differences in myogenin mRNA 
levels in simvastatin-treated C2C12.45 We, however, found 
myogenin protein expression to be impaired in primary dif-
ferentiating myoblasts treated with atorvastatin. Moreover, 
our results in GILZ KO myoblasts indicate that statin-in-
duced GILZ expression, and the consequent myogenin tran-
scriptional repression, is a mechanism by which this class of 
drugs impairs myogenesis.
GILZ silencing by shRNA caused the resulting C2C12shGilz 
cell lines to differentiate considerably faster than the C2C12scr 
control, even to a higher degree than observed for WT cells 
after terminal differentiation. This supports the importance 
F I G U R E  8  Effects of statins and GILZ on zebrafish muscle development. A, Zebrafish embryos at 20 hpf were treated with simvastatin 
lactone (1 µM) or cerivastatin (1 µM) for 12 hours. mRNA expression was normalized to the housekeeping gene (actb2) and is presented as fold 
change of control ± SEM (n = 3, duplicates). B, Zebrafish embryos at the 1-2 cell stage were treated with simvastatin lactone (1 µM) or cerivastatin 
(1 µM) for 24 hours, and muscle contractions per minute were counted (n ≥ 10) and are presented as means ± SEM. C-D, 1 ng statin or vehicle 
(Co) were injected into zebrafish embryos in the 1-2 cell stage. C, MHC IF of statin-treated and gilz-overexpressing 24 hpf embryos. Representative 
images are shown. A diffuse staining and a complete loss of the V-shaped somite pattern was observed in all simvastatin- or gilz mRNA-treated 
embryos (n ≥ 10 per group). Panels are side views. Red: MHC, scale bar: 50 µm. D, MyoD in situ hybridization of statin treated and gilz-
overexpressing 16 hpf embryos shows a severely impaired MyoD expression when compared to control. Representative images are shown. Panels 
are dorsal views. Violet: MyoD, scale bar: 60 µm. E: Phenotypic scoring of MyoD-stained embryos (n = 7-10 per group). *P < .05, **P < .01, 
***P < .001, relative to the control 
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of GILZ itself as a modulator of myogenesis and corresponds 
to our observations in zebrafish embryos, where gilz over-
expression severely impaired somitogenesis. Importantly, 
zebrafish embryos represent a frequently used in vivo model 
for the mechanistic study of SAMS.50-52,63 The regulatory 
role played by GILZ in zebrafish embryonic development is 
rather complex: the study that first described the presence of 
a GILZ orthologue in zebrafish showed that manipulation of 
gilz expression in this model, either via morpholino oligo-
mer silencing or mRNA overexpression, causes significant 
defects in embryonic development, altering the dorsoventral 
patterning, segmentation, and brain development processes.53 
In rodents, however, GILZ-independent regulatory pathways 
are most likely involved in the modulation of skeletal mus-
cle development, since GILZ KO mice do not exhibit altered 
muscle features (unpublished observations).
Even though myogenin expression was rescued in the ab-
sence of GILZ, we could not observe a complete recovery 
in myotube formation after statin treatment in C2C12shGilz 
cells. This might be related to residual GILZ expression in 
the silenced cells, or to additional pathways that mediate the 
antimyogenic effects observed, such as the IGF-1/PI3K/Akt 
pathway.46 Our observations indicate that GILZ is critical for 
statin-induced inhibition of myogenin, an MRF crucial for 
myoblast fusion and terminal differentiation.64 Additional 
factors, however, may also contribute to the inhibition of 
muscle regeneration by statins.
Taken together, our data point toward GILZ as an es-
sential mediator of the molecular mechanisms leading to 
statin-induced muscle damage and impairment of muscle 
regeneration. This study contributes to a better understand-
ing of the molecular mechanisms underlying statin-induced 
myopathy, a necessary step toward the development of pre-
vention strategies, and safer therapy approaches for a class 
of drugs that remains a pillar in the treatment of cardiovas-
cular disease.
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